Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Bought by Dark Forest Capital Management LP

Dark Forest Capital Management LP raised its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 16.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,386 shares of the biotechnology company’s stock after buying an additional 8,557 shares during the period. Dark Forest Capital Management LP’s holdings in Ironwood Pharmaceuticals were worth $394,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC increased its position in shares of Ironwood Pharmaceuticals by 45.7% during the second quarter. AQR Capital Management LLC now owns 684,578 shares of the biotechnology company’s stock worth $4,463,000 after purchasing an additional 214,836 shares in the last quarter. Armistice Capital LLC increased its position in shares of Ironwood Pharmaceuticals by 44.4% during the second quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock worth $50,856,000 after purchasing an additional 2,400,000 shares in the last quarter. Public Sector Pension Investment Board increased its position in shares of Ironwood Pharmaceuticals by 9.3% during the second quarter. Public Sector Pension Investment Board now owns 307,786 shares of the biotechnology company’s stock worth $2,007,000 after purchasing an additional 26,168 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Ironwood Pharmaceuticals by 23.6% during the second quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock worth $58,078,000 after purchasing an additional 1,701,452 shares in the last quarter. Finally, Inspire Investing LLC increased its position in shares of Ironwood Pharmaceuticals by 34.1% during the second quarter. Inspire Investing LLC now owns 54,677 shares of the biotechnology company’s stock worth $356,000 after purchasing an additional 13,908 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on IRWD shares. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 target price on the stock. Craig Hallum lowered their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Capital One Financial lowered Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Finally, Wells Fargo & Company lowered their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.17.

Ironwood Pharmaceuticals Trading Down 1.0 %

Shares of IRWD opened at $4.02 on Friday. Ironwood Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $15.70. The stock’s 50 day moving average is $5.07 and its two-hundred day moving average is $6.46. The firm has a market capitalization of $629.25 million, a PE ratio of -0.59 and a beta of 0.49.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the sale, the insider now owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.90% of the stock is owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.